Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Pfizer lays out oncology direction; key topics at BIO 2026; GLP-1 access causes problems for obesity studies; GLP-1 use insights from Brazil; and Q1’s top 10 drugs.
Scrip - June 22, 2026

Stroke Therapy Using Robotic Exoskeletons Linking Therapist And Patient Shows Promise
A new study from Northwestern University and Shirley Ryan AbilityLab shows early promise for a new rehabilitation system that virtually connects therapists and stroke patients through robotic exoskeletons.
Medtech Insight - June 19, 2026

Diagnostics and Surveillance Gaps Drive UK’s New Outbreak-Response Network
The Multi-Hazard Research Network merges social science with epidemiology to tackle cascading hazards — showing why treating disease alone is never enough.
Medtech Insight - June 19, 2026

US FDA Warns Revlon, Fragrance Creators Holds Fly-In; News Roundup
Revlon Group Holdings did not properly test talc components in a drug product for asbestos, according to the US Food and Drug Administration.
HBW Insight - June 22, 2026

US FDA’s Stelo Pediatric Clearance Marks First OTC CGM For Children, Backed By Real-World Data
The FDA has cleared Dexcom's Stelo continuous glucose monitor for OTC use by children ages 2 and up who do not use insulin, making it the first nonprescription CGM cleared for pediatric use. The authorization was supported in part by real-world evidence.
HBW Insight - June 22, 2026

Message Received: European Parliament Backs Industry Push For UWWTD Pause
At Medicines for Europe’s annual conference in Athens last week, industry leaders called for a halt on implementing the controversial Urban Waste Water Treatment Directive. Yesterday, the European Parliament voted in favor of a pause. And multiple EU-level legal cases are also pursuing challenges.
Generics Bulletin - June 19, 2026

First Xofluza Generic Approved In The US
The US FDA approved the first single-dose generic treatment for influenza, a rival to Genentech’s Xofluza from Norwich Pharmaceuticals, in time for the 2026-2027 flu season.
Generics Bulletin - June 19, 2026

Aurobindo Gets FTC Go-Ahead For Lannett Takeover – But With Strings Attached
Aurobindo expects to complete its pending acquisition of Lannett by the end of the month after the US Federal Trade Commission approved the deal – conditional on four product divestments.
Generics Bulletin - June 19, 2026

Brazil Builds Biosimilar Momentum With Eylea, Stelara Rivals
Brazil’s Anvisa has approved Celltrion’s Eydenzelt and SteinCares’ Uztok, adding a second Eylea biosimilar and another Stelara rival as the country’s biosimilar market gains policy and regulatory momentum.
Generics Bulletin - June 19, 2026

Weber Transformed Takeda - At A Cost
As Christophe Weber prepares to step down as CEO of Takeda this week after 11 years, Scrip takes a look back at his time at the helm, how the company has transformed, and successor Julie Kim's initial priorities.
In Vivo - June 21, 2026